Table 2.
First subsequent systematic therapy for PC (intent‐to‐treat population)
| Japanese subpopulation (N = 51) | Overall population† (N = 1052) | |||
|---|---|---|---|---|
|
Apalutamide (n = 28) |
Placebo (n = 23) |
Apalutamide (n = 525) |
Placebo (n = 527) |
|
| Duration of first subsequent therapy (days), median (range) | 126 (48–375) | 145 (61–637) | 95 (1–403) | 119 (1–648) |
| Number of patients alive at treatment discontinuation, n | 12 | 18 | 247 | 345 |
| Number of patients with first subsequent systemic therapy for PC, n (%) | 7 (58.3) | 13 (72.2) | 120 (48.6) | 221 (64.1) |
| Hormonal | 6 (50.0) | 8 (44.4) | 58 (23.5) | 124 (35.9) |
| Bicalutamide | 4 (33.3) | 5 (27.8) | 16 (6.5) | 30 (8.7) |
| Abiraterone acetate plus prednisone | 2 (16.7) | 2 (11.1) | 27 (10.9) | 65 (18.8) |
| Enzalutamide | 0 | 1 (5.6) | 9 (3.6) | 24 (7.0) |
| Chemotherapy | 1 (8.3) | 4 (22.2) | 50 (20.2) | 88 (25.5) |
| Docetaxel | 1 (8.3) | 4 (22.2) | 42 (17.0) | 78 (22.6) |
| Other | 1 (8.3) | 2 (11.1) | 32 (13.0) | 63 (18.3) |
| Prednisolone | 1 (8.3) | 1 (5.6) | 6 (2.4) | 12 (3.5) |
| Radium‐223 | 0 | 1 (5.6) | 5 (2.0) | 5 (1.4) |
†
Data are from Chi et al. 14